The Difficult-to-Express Proteins Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Difficult-to-Express Proteins Market:
https://www.thebusinessresearchcompany.com/report/difficult-to-express-proteins-global-market-report
According to The Business Research Company’s Difficult-to-Express Proteins Global Market Report 2024, The difficult-to-express proteins market size has grown rapidly in recent years. It will grow from $4.11 billion in 2023 to $4.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising demand for protein therapeutics, drug development challenges, biopharmaceutical advancements, technological limitations, gene editing and engineering.
The difficult-to-express proteins market size is expected to see rapid growth in the next few years. It will grow to $7.09 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to novel expression systems development, next-generation gene editing tools, improved cell-free systems, enhanced protein engineering, ai and machine learning integration. Major trends in the forecast period include innovative protein folding technologies, expanded use of synthetic biology, targeted protein modification, biophysical characterization advances, increased use of crispr/cas technology.
Rising demand for recombinant proteins is expected to propel the growth of the difficult-to-express protein market going forward. Recombinant protein is created using recombinant DNA (deoxyribonucleic acid), or DNA that has undergone modification to produce the genetic code of a protein of desire. Difficult-to-express proteins are used in recombinant protein synthesis to examine their specific activities, protein-protein interactions, and the development of innovative therapeutics for complex medical diseases. For instance, in 2022, according to the annual report published by Amgen Inc., a US-based biopharmaceutical company, Prolia (Denosumab), a recombinant human monoclonal antibody (protein), witnessed 12% growth in annual sales, generating $3,628 million in 2022, compared with $3,248 million in 2021. Therefore, the rising demand for recombinant proteins propels the growth of the difficult-to-express protein market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12602&type=smp
The difficult-to-express proteins market covered in this report is segmented –
1) By Protein: Proteases, Kinases, Membrane Proteins, Other Proteins
2) By Expression Of Difficult Proteins: Disulfide-bonded Protein Expression, Membrane Protein Expression, Toxic Protein Expression, Target Protein Insolubility
3) By Technology: Cell-free Protein Synthesis, Prokaryotic Expression Systems, Small Ubiquitin-like Modifier (SUMO) Fusion System, Gene Fusion Systems, Other Technologies
4) By Application: Drug Discovery, Protein Purification, Protein Therapeutics, Disease Diagnostics And Monitoring, Other Applications
The development of innovative technologies is a key trend gaining popularity in the difficult-to-express protein market. Major companies operating in the difficult-to-express protein market are focused on developing innovative technologies to sustain their position in the market. For instance, in January 2023, Evozyne, a US-based biotechnology company, developed an innovative AI model called Protein Transformer Variational AutoEncoder to design therapeutic proteins. This technique creates a framework for effectively training and deploying big language models for biology. The end resultant model is an innovative take on deep learning that brings up new possibilities for the data-driven design of engineered proteins with designed functionality.
The difficult-to-express proteins market report table of contents includes:
1. Executive Summary
2. Difficult-to-Express Proteins Market Characteristics
3. Difficult-to-Express Proteins Market Trends And Strategies
4. Difficult-to-Express Proteins Market – Macro Economic Scenario
5. Global Difficult-to-Express Proteins Market Size and Growth
.
.
.
26. South America Difficult-to-Express Proteins Market
27. Brazil Difficult-to-Express Proteins Market
28. Middle East Difficult-to-Express Proteins Market
29. Africa Difficult-to-Express Proteins Market
30. Difficult-to-Express Proteins Market Competitive Landscape And Company Profiles
Top Major Players:
- Thermo Fisher Scientific Inc
- Merck KGaA
- Lonza Group Ltd
- Catalent Inc
- Sartorius AG
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
